MRZM (Marizyme) Tax Expense: $0.00 Mil (TTM As of Sep. 2024)


MRZM Marizyme Inc MRZM
12 GF Score
Price $0.00
View Full Analysis

What is Marizyme Tax Expense?

Marizyme MRZM -99.67% 12 Tax Expense is $0.00 Mil as of Sep. 2024. GuruFocus rates MRZM with a GF Score™ of 12/100.

Marizyme's tax expense for the months ended in Sep. 2024 was $0.00 Mil. Its tax expense for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.


Marizyme  (OTCPK:MRZM) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Marizyme Tax Expense Related Terms


Marizyme Tax Expense Historical Data

* Premium members only.

The historical data trend for Marizyme's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marizyme Tax Expense Chart

Marizyme Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Marizyme Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MRZM
12GF Score
Marizyme Inc MRZM
Tax Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Marizyme Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Expense →
What does a Tax Expense of $0.00 Mil mean?
Marizyme (MRZM) has a Tax Expense of $0.00 Mil as of Sep. 2024. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Marizyme and its competitors.
Is Marizyme's Tax Expense too high?
Marizyme's current Tax Expense is $0.00 Mil. Overall, Marizyme has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Marizyme's Tax Expense compare to CNBX and XSNX?
Marizyme's Tax Expense of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Expense for a Biotechnology company?
A good Tax Expense depends on the Biotechnology industry context. However, Tax Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Expense mean?
A high Tax Expense can signal that a stock is expensive relative to its fundamentals. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Marizyme and its competitors. Marizyme's current Tax Expense is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marizyme stock overvalued right now?
Marizyme (MRZM) has a current Tax Expense of $0.00 Mil. The current Tax Expense is $0.00 Mil. Marizyme's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Expense calculated?
Tax Expense is calculated from a company's financial statements. For Marizyme (MRZM), the current Tax Expense is $0.00 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Marizyme Business Description

Address 555 Heritage Drive, Suite 205, Jupiter, FL, USA, 33458
Marizyme Inc is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical device technologies that improve patient health outcomes. Currently, the company is focused on developing three medical technology products: DuraGraft, Krillase, and MATLOC. DuraGraft is a single-use intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure, MATLOC is a point-of-care, lab-on-chip digital screening, and diagnostic device platform, initially being developed for quantitative chronic kidney disease, or CKD, assessment, and Krillase protein enzyme provides a therapeutics opportunity for wound healing, thrombosis, and pet health.
12GF Score

Get the complete analysis for MRZM

Tax Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price